EX-99.1 2 f8k033115ex99i_oxysure.htm PRESS RELEASE

Exhibit 99.1


OxySure Logo 7


Conference Call at 9:00 am ET on March 31, 2015


Frisco, Texas, March 31, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), today announced financial and operating results for the fourth quarter and year ended December 31, 2014.


Fiscal Year 2014 Highlights:


Revenues were $2.4 million, up 35%, led by an 83% increase in revenues in the US
10th consecutive quarter of sales growth
Gross profit was 56% on an adjusted basis
General & administrative expense was $1.75 million
Cash was at $647,093
Capital leases decreased by $309,534
Long term debt down 42%
Working capital was a surplus of $418,734
Current ratio was 1.3
Total assets increased 7% to $2.5 million
Net loss per share for the year was $0.10
Model 615 shipments up 18%; Replacement cartridge shipments up 35%
Replacement cartridges up to 144% of Model 615 shipped


Julian T. Ross, Chairman of the Board and Chief Executive Officer of OxySure stated, “We are pleased to have grown the business once again, while remaining focused on building a solid medical device platform to leverage growth opportunities going forward. We are now remarkably well-positioned as an emerging medical device leader to achieve our goals for 2015 and beyond. These goals include rapidly growing our direct sales force, expanding overseas, launching a direct to consumer (DTC) campaign, uplisting our company to NYSE or Nasdaq, and making strategic acquisitions.”


For the fiscal year ended December 31, 2014, revenues increased by 35% to $2,437,402 from $1,800,327 in 2013. The increase was primarily driven by an 83% surge in revenues in the United States. The revenue increase in the US was driven primarily by an increase in sales from products for the military in connection with a teaming agreement.


For the Company’s Model 615 portable emergency oxygen product, unit cartridge reorder rates continued to increase as the installed base of Model 615 increases, continuing the trend of a very “sticky” customer relationship with the product upon adoption. Unit cartridge shipments as a percentage of Model 615 shipments increased to 144% in FY2014 from 125% in FY2013. Cartridges as a percentage of the Model 615 installed base as at December 31, 2014 increased to 45%, up from 39.3% as at December 31, 2013. During FY2014, Model 615 shipments increased 18% versus FY2013, and replacement cartridge shipments increased 35% versus FY2013. This continues to be consistent with historical trends of rising reorders as customers become more accustomed to OxySure’s products.




Gross profit was $1,018,355 for the twelve months ended December 31, 2014, a decrease of 15.7% from $1,207,341, primarily due to the effect of an increase in absorbed rent expense and labor cost. Adjusted for these rent and labor expenses gross profit was $1,352,746 representing a gross margin of 56%.


Selling, general and administrative expenses for 2014 were $2,469,711 compared to $1,339,624 for fiscal year 2013. The Company increased sales and marketing expenses by 104% to $718,705 as it expanded its sales and marketing, branding and investor relations efforts. General and administrative expenses also increased by 78% to $1,751,006 primarily as a result of an increase in employee stock option expense, an increase in salaries and wages, and an increase in professional fees. Professional fees increased primarily due to legal and accounting fees related to an acquisition transaction the Company pursued during the second half of 2014 but did not consummate during FY2014.


Interest expense increased to approximately $907,612 in the twelve months ended December 31, 2014, as compared to $249,979 in the twelve months ended December 31, 2013, primarily as a result of the amortization of debt discount and beneficial conversion features (BCF). The Company recorded approximately $747,612 in non-cash interest related to debt discount amortization during the twelve months ended December 31, 2014, as compared to $207,239 during the twelve months ended December 31, 2013.


Net loss during fiscal year ended December 31, 2014 was $2,753,560, or $0.10 per share, as compared to $712,452 or $0.03 per share for fiscal year ended December 31, 2013. The weighted average shares outstanding were 26,367,254 and 23,754,402 for fiscal year 2014 and 2013, respectively.


The Company’s balance sheet remained strong. Cash was $647,093 at December 31, 2014 as compared to $657,673 at December 31, 2013. Working capital was a surplus of $418,734 at December 31, 2014 as compared to a surplus of $747,473 at December 31, 2013. The Company’s current ratio was 1.3 as at December 31, 2014. Cash from financing activities was down 24% to $1.16 million during FY2014 from $1.52 million during FY2013.


The Company had deferred income tax assets of $5,588,365 and $4,733,483 for the years ended December 31, 2014 and 2013 respectively which were offset in full by a valuation allowance.




Business updates


OxySure enters 2015 in a remarkably strong position as an emerging medical device leader. Over the past 12 months, the Company:


Expanded its international distribution footprint by adding new distributors such as HTM Medico for Singapore, and Ajad Medical for Saudi Arabia;
Received CE Mark Approval for the OxySure Model 615 Portable Emergency Oxygen Device, a critical step toward launching the product into the 30 countries belonging to the European Economic Area (EEA);
Appointed several new US distributors;
Commenced a pilot for a cloud-based tracking and incident reporting system;
Made significant progress on the development of new products for the military;
Secured Cliff Meidl, two-time Olympian and Team USA Olympic Flag Bearer to be a Spokesman and Special Advisor exclusively to the Company;
Was selected by the United States Patent and Trademark Office (USPTO) as one of 10 companies, including Caterpillar, Qualcomm and others to exhibit its product and related technologies at the Innovation Expo held at the Smithsonian;
Made significant staffing additions to enhance medical device platform capability, including a VP of Resuscitation Sales, Director of Regulatory Affairs and Quality Assurance, and additions in engineering, manufacturing and territory sales management; and
Opportunistically invested in operational efficiencies.


The Company plans to continue its focus on growth by expanding its direct sales force and its global distribution channel. The Company also plans to ramp up its sales and marketing activities to raise market awareness and grow its brand, while maintaining a focus on regulatory approvals and compliance and reductions in product costs and operational costs. These initiatives and investments will result in higher sales for OxySure in the future, and at the same time expand OxySure’s leadership position in the emergency/short-duration oxygen market and the pre-hospital medical emergency market in general.


“We are excited about 2015 as we anticipate continued growth, new opportunities and even the possibility of catalytic events,” said Mr. Ross. “We plan to continue to work hard to improve our products, our competitive position, and our category leadership, while striving to maintain our culture of innovation as we grow.”




Conference Call


OxySure’s CEO Julian Ross will host the conference call to discuss the Company’s fiscal year 2014 results.


Date: Tuesday, March 31, 2015
Time: 9:00 am ET
US Dial-In: 1 (800) 697-5978 Audience US Toll Free
International Dial-In: 1 (630) 691-2750 Audience US Toll
Passcode: 6079 959#
For webcast link: http://www.oxysure.com/aed/index.php/investors-home


Please dial in at least 10-minutes before the call to ensure timely participation.


About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com


Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.




   December 31, 
   2014   2013 
Current assets        
Cash and cash equivalents  $647,093   $657,673 
Accounts receivable, net   369,575    47,183 
Inventories   277,346    287,666 
License fee receivable   463,308    500,000 
Prepaid expenses and other current assets   53,588    107,305 
Total current assets   1,810,910    1,599,827 
Property and equipment, net   91,537    70,249 
Intangible assets, net   362,764    392,746 
Other assets, net   246,237    289,532 
TOTAL ASSETS  $2,511,448   $2,352,354 
Current liabilities          
Accounts payable and accrued expenses  $558,338   $147,719 
Related party payable   154,850    118,627 
Deferred revenue   -    2,976 
Capital leases - current   149    309,129 
Notes payable - current, net of discount   40,897    44,000 
Convertible notes payable, net of discount   637,942    229,903 
Total current liabilities   1,392,176    852,354 
Long-term liabilities          
Capital leases   -    554 
Notes payable, net of discount   44,484    76,072 
Total long-term liabilities   44,484    76,626 
TOTAL LIABILITIES   1,436,660    928,980 
Preferred stock, par value $0.0005 per share; 25,000,000 shares authorized;          
593,750 Series A convertible preferred shares issued and outstanding as of December 31, 2014 and 743,750 shares issued and outstanding as of December 31, 2013.   296    371 
1,145 Series B convertible preferred shares issued and outstanding as of December 31, 2014 and 750 shares issued and outstanding as of December 31, 2013.   1    - 
Common stock, par value $0.0004 per share; 100,000,000 shares authorized;          
28,438,631 shares of voting common stock issued and outstanding as of December 31, 2014 and 25,854,307  shares issued and outstanding as of December 31, 2013   11,377    10,343 
Additional Paid-in Capital   19,104,322    16,700,307 
Accumulated deficit   (18,041,208)   (15,287,647)
TOTAL STOCKHOLDERS’ EQUITY   1,074,788    1,423,374 



   For the year ended
December 31,
   2014   2013 
Revenues, net  $2,437,402   $1,800,327 
Cost of goods sold   1,419,047    592,986 
Gross profit   1,018,355    1,207,341 
Operating expenses          
Research and development   583,435    356,015 
Sales and marketing   718,705    353,156 
Other general and administrative   1,751,006    986,468 
Loss from operations   (2,034,791)   (488,298)
Other income (expenses)          
Other income (expense)   188,843    25,825 
Interest expense   (907,612)   (249,979)
Total other income (expenses)   (718,768)   (224,154)
Net loss  $(2,753,560)  $(712,452)
Basic net income (loss) per common share  $(0.10)  $(0.03)
Diluted net income (loss) per common share  $(0.10)  $(0.03)
Weighted average common shares outstanding:          
Basic   26,367,254    23,754,402 
Diluted   26,367,254    23,754,402 



   Year Ended December 31, 
   2014   2013 
Net income (loss)  $(2,753,560)  $(712,452)
Adjustments to reconcile net income (loss) to net          
cash from operating activities:          
Depreciation and amortization expense   42,151    53,159 
Amortization of debt discount and beneficial conversion features   747,612    207,239 
Gain on forgiveness of debt   14,466    - 
Gain on settlement of debt   (90,912)   - 
Derivative liability fair value adjustment   3,001    - 
Expenses paid by related parties   4,374    37,335 
Expenses paid on behalf of third party   150,000    - 
Stock based compensation   136,944    61,480 
Common stock issued for services   64,873    126,756 
Changes in operating assets and liabilities:          
Accounts receivable   (322,392)   (28,697)
Inventories   10,320    (66,321)
License fees receivable   36,692    (500,000)
Other assets   125,531    106,148 
Accounts payable and accrued liabilities   763,046    (72,601)
Prepaid expense   (28,519)   - 
Deferred revenue   (2,976)   (72,837)
Purchase of property and equipment   (68,080)   (12,105)
Purchase of intangible assets   (198)   (4,262)
Common stock issued for cash   29,701    347,364 
Series B preferred stock issued for cash and warrants   525,000    750,000 
Common stock issued for cash and warrants   -    216,800 
Cash received from related parties   9,800    42,470 
Payments made to related parties   (227,951)   (268,950)
Payments made on notes payable   -    - 
Cash received from convertible notes payable   1,168,200    431,500 
Payments made on convertible notes payable   (200,201)   - 
Payments on capital leases   (151,872)   (2,254)
Exercising of warrants   4,370    4,388 
Net change in cash and cash equivalents   (10,580)   644,160 
Cash and cash equivalents, at beginning of period   657,673    13,513 
Cash and cash equivalents, at end of period  $647,093   $657,673 
Supplemental disclosure of cash flow information:          
Cash paid during the period for:          
Interest  $-   $18,792 
Income taxes  $-   $- 
Supplemental non-cash investing and financing activities:          
Initial value of derivative  $28,009   $- 
Capitalization of deferred loan costs   -    48,012 
Common stock issued for services and rent extension   -    179,710 
Common stock issued for capitalized website development costs   -    114,180 
Common stock issued in connection with lease extinguishment   66,750    - 
Cashless exercise of warrants for forgiveness of debt   -    14,700 
Conversion of convertible notes payable   625,913    447,748 
Benefical conversion feature   951,423    317,609 
Conversion of Series A preferred stock to common stock   74    38 
Conversion of accrued rent to common stock   -    423,413 





Renmark Financial Communications, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com

John Boidman: jboidman@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989



Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107